Circulating pre-osteoclasts are primed for osteoclast fate and synovial tissue homing in psoriatic arthritis.

This study identifies a distinct circulating pre-osteoclast population derived from classical monocytes that is expanded in active psoriatic arthritis, primed for osteoclast differentiation without exogenous RANKL, and actively recruited to inflamed synovial tissue, thereby elucidating the systemic immune mechanisms driving bone erosion in the disease.

The Gist

The Big Picture: A Case of "False Alarms" in the Body

Imagine your body is a bustling city. In this city, there are special construction crews called Osteoclasts. Their job is usually very helpful: they are the "demolition experts" who gently tear down old, worn-out bone so new, strong bone can be built. It's a normal part of maintenance, like a city tearing down an old bridge to build a new one.

But in a disease called Psoriatic Arthritis (PsA), something goes wrong. The demolition crews go into a frenzy. Instead of just fixing small cracks, they start smashing down entire walls, causing painful bone erosion and joint damage.

For a long time, scientists knew these "demolition crews" were causing the damage, but they didn't know who was sending them to the construction site. They assumed the crews were recruited after they arrived at the joint, like workers being hired on the spot.

This paper reveals a shocking new truth: The workers are already "primed" (pre-trained) for destruction before they even leave the factory (the bloodstream).

---

The Story Unfolds: From Factory to Battlefield

1. The "Pre-Construction" Workers (Pre-Osteoclasts)

The researchers discovered a specific type of white blood cell called a pre-osteoclast (or "preOC"). Think of these as apprentice demolition experts.

• In a healthy person: These apprentices are calm. They hang out in the blood, waiting for a specific signal (like a foreman shouting "Start work!") before they become active demolition crews.
• In a PsA patient: These apprentices are already wearing their hard hats, holding their sledgehammers, and revving their engines while they are still in the bloodstream. They are "primed" for destruction. They don't need to wait for the signal at the joint; they are ready to go the moment they arrive.

2. The GPS System Gone Wild (Homing Signals)

How do these workers know where to go? They have a GPS system on their surface made of special markers (proteins).

• The Analogy: Imagine the inflamed joint in a PsA patient is a city under attack, sending out a loud radio broadcast saying, "We need demolition crews here! We have a crisis!"
• The Discovery: The researchers found that the PsA apprentices have their GPS tuned specifically to this "Crisis Frequency." They have extra antennas (markers like CCR3, CCR4, etc.) that make them super-sensitive to the joint's distress signal.
• The Result: While healthy workers ignore the radio, the PsA workers hear it loud and clear and immediately rush to the joint.

3. The "Self-Start" Engine (RANKL Independence)

Usually, to turn an apprentice into a full demolition crew, you need a specific key called RANKL. It's like a safety switch that must be flipped to start the engine.

• The Surprise: The researchers found that the PsA pre-osteoclasts have a bypass switch. They can start their engines and start destroying bone without needing the key (RANKL). They are so "primed" that they can do the job on their own. This explains why the damage happens so fast and aggressively in PsA.

4. The Investigation: Tracking the Suspects

To prove this, the scientists used some high-tech detective work:

• The Radioactive Tag: They took blood from patients, labeled the monocytes (the precursor cells) with a tiny, safe radioactive tag (like putting a GPS tracker on a suspect), and put the blood back into the patient.
• The Camera: They watched where the tagged cells went.
  • Healthy people: The tags stayed in the blood or went to the liver/spleen. They didn't go to the joints.
  • PsA patients: The tags migrated straight to the inflamed joints.
• The Microscope: They took a biopsy of the joint tissue and used a super-powerful microscope (Imaging Mass Cytometry) to look at the tagged cells.
  • The Smoking Gun: The tagged cells they found inside the joint were not just regular workers; they were the "primed" demolition crews (pre-osteoclasts), and they were already fused together, ready to destroy bone.

Why Does This Matter?

This study changes how we think about Psoriatic Arthritis.

1. It's a Systemic Problem: The problem isn't just in the joint; it's happening in the bloodstream first. The immune system is "priming" these cells to attack bone before they even reach the site of injury.
2. New Targets for Medicine: Currently, drugs try to stop the inflammation or block the "key" (RANKL). But if the workers are already primed and have a bypass switch, those drugs might not be enough.
3. Future Hope: This opens the door for new treatments that could:
   • Stop the "priming" in the blood (so the workers never get their sledgehammers).
   • Jam the GPS (so they can't find the joint).
   • Disarm the bypass switch.

The Takeaway

In Psoriatic Arthritis, the body's own demolition crew is being trained to be violent while it's still in the blood. They arrive at the joint fully armed and ready to destroy bone without needing permission. By understanding this "pre-priming," scientists hope to stop the destruction before it even begins.

Technical Summary

1. Problem Statement

Psoriatic Arthritis (PsA) is a heterogeneous immune-mediated inflammatory disease characterized by joint inflammation and pathological bone erosion. While osteoclasts (multinucleated bone-resorbing cells) are known to drive bone destruction, the precise identity of their circulating human precursors has remained elusive.

• The Gap: It is unclear whether monocytes are recruited to inflamed joints in PsA, what specific phenotype they possess upon recruitment, and whether they are "primed" for osteoclast differentiation before entering the tissue.
• The Challenge: Multinucleated osteoclasts are difficult to study in vivo due to technical limitations in isolating them from tissue. Previous studies relied heavily on in vitro models or murine data, which may not fully translate to human disease mechanisms.
• The Question: Do circulating monocytes in PsA patients possess a distinct, pre-committed "pre-osteoclast" (preOC) state that facilitates their homing to synovial tissue and rapid differentiation into bone-destroying cells?

2. Methodology

The study employed a multi-modal, translational approach combining clinical imaging, advanced single-cell genomics, proteomics, and functional assays.

• Clinical Imaging & Radiolabelling:

  • Technique: Autologous monocytes from healthy volunteers and active, treatment-naïve PsA patients were radiolabelled with Technetium-99m (Tc99m-HMPAO).
  • Application: Planar imaging tracked the migration of these cells to inflamed vs. non-inflamed joints over 24 hours.
  • Validation: Synovial biopsies were taken 24 hours post-injection from PsA patients.

• Single-Cell & Bulk Omics:

  • Bulk RNA-seq: Performed on sorted monocyte subsets (classical, intermediate, non-classical) and dendritic cells from healthy vs. PsA blood to identify tissue-homing markers.
  • Mass Cytometry (CyTOF): Used to profile protein expression on peripheral blood mononuclear cells (PBMCs) to identify rare populations based on surface markers (e.g., DCSTAMP).
  • scRNA-seq (VASA-seq): High-depth single-cell sequencing of FACS-sorted monocytes and preOCs from blood to define transcriptomic trajectories.
  • Synovial Atlas: Integration of the authors' new scRNA-seq data from PsA synovium with 6 public datasets (RA, OA, Healthy) to create a reference atlas of 638,506 cells.
  • Spatial Transcriptomics (10x Xenium): Performed on synovial biopsies to map cell locations and gene expression within the tissue architecture.

• Functional Assays:

  • In Vitro Differentiation: Sorted classical monocytes (cMos) and preOCs were cultured with M-CSF and/or RANKL to assess osteoclast formation (TRAP staining, multinucleation).
  • Radiolabel Detection: Imaging Mass Cytometry (IMC) was used to detect Tc99m signals in cultured cells and synovial tissue sections, linking circulating cells to tissue phenotypes.

• Computational Analysis:

  • Trajectory Inference: Used Slingshot and scTour (deep learning) to model differentiation paths from monocytes to preOCs.
  • Integration: Used CellHint and scVI to harmonize datasets across different donors and disease states.

3. Key Contributions

• Discovery of Circulating preOCs: Identification of a distinct, rare population of circulating "pre-osteoclasts" (preOCs) in humans, defined by high expression of DCSTAMP and NFATC1.
• Proof of Systemic Priming: Demonstration that the osteoclast fate is determined before cells reach the joint. PsA preOCs are transcriptionally distinct from classical monocytes and can form osteoclasts without exogenous RANKL.
• Homing Mechanism: Identification of a specific "synovial tissue homing" signature (integrins, chemokine receptors like CCR3/4/9/10) on preOCs that drives their preferential recruitment to inflamed PsA joints.
• Novel Imaging Technique (MASS-seq): Development of a method to trace radiolabelled circulating cells into tissue and phenotype them using Imaging Mass Cytometry, confirming that radiolabelled cells co-localize with osteoclast-lineage cells in the synovium.

4. Key Results

• Monocyte Recruitment: Radiolabelling confirmed that monocytes specifically accumulate in clinically inflamed joints of PsA patients but not in healthy joints or non-inflamed joints of PsA patients.
• Phenotypic Characterization:
  • Proteomics: CyTOF revealed a distinct preOC population (DCSTAMP-high) and an "adhesion-enriched" monocyte population in PsA blood.
  • Transcriptomics: scRNA-seq showed preOCs are transcriptionally distinct from classical monocytes, upregulating osteoclastogenesis genes (NFATC1, DCSTAMP, ACP5, CTSK) and downregulating monocytic markers (CD14, S100A8/9).
  • Trajectory: Pseudotime analysis confirmed a linear trajectory from classical monocytes $\rightarrow$ preOC-1 $\rightarrow$ preOC-2.
• Functional Potency:
  • Sorted preOCs formed multinucleated TRAP-positive osteoclasts in vitro without the addition of exogenous RANKL (unlike classical monocytes, which required RANKL).
  • PsA preOCs showed higher expression of osteoclast-related genes compared to healthy preOCs, suggesting disease-specific hyper-priming.
• Tissue Homing:
  • PreOCs express a robust panel of tissue-homing receptors (CCR3, CCR4, CCR9, CCR10, CXCR4, ITGAV, ITGB3) matching the profile of cells found in inflamed synovium.
  • Spatial transcriptomics of PsA synovium showed an enrichment of preOCs and osteoclast-lineage cells (OCL-1, OCL-2) compared to healthy tissue.
• Direct Tracing: In one PsA donor, Imaging Mass Cytometry detected Tc99m-positive foci within the synovial lining layer. These foci co-localized with cells expressing osteoclast lineage markers, providing direct evidence that circulating preOCs migrate to and reside in the inflamed joint.

5. Significance

• Mechanistic Insight: The study shifts the paradigm of bone erosion in PsA from a purely local tissue event to one driven by systemic immune priming. The disease state alters the circulating monocyte pool, creating a reservoir of "ready-to-differentiate" cells.
• Therapeutic Implications:
  • Current therapies target cytokines (TNF, IL-17, IL-23) but often fail to fully prevent bone erosion.
  • The identification of preOCs and their homing receptors suggests new therapeutic targets: blocking the recruitment of preOCs to the joint or inhibiting their systemic priming could prevent structural damage more effectively than targeting downstream osteoclast activity alone.
• Technical Advancement: The successful application of radiolabelling combined with Imaging Mass Cytometry (termed "MASS-seq" by the authors) offers a powerful new tool for tracing cell migration and fate in human immunology, overcoming previous limitations in studying rare, transient cell states in vivo.
• Biomarker Potential: Circulating preOCs could serve as a biomarker for predicting disease progression or bone erosion risk in PsA patients, distinguishing those with active joint disease from those with only cutaneous psoriasis.

In summary, this paper defines a distinct, circulating human pre-osteoclast population that is systemically primed in Psoriatic Arthritis, equipped with homing receptors for synovial tissue, and capable of driving bone destruction independently of local RANKL signaling.